Healthcare
PaxMedica, Inc. Common Stock(PXMD)
Live Price
Offline$0.0007
+40.00% today
1Y Change
+600.00%
Window
Jun 23, 2025 → Jun 17, 2026
- Market Cap
- —
- Revenue Growth
- 0.0%
- EPS Growth
- +61.7%
- Dividend Yield
- 0.0%
Coverage: 247 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PaxMedica, Inc. Common Stock (PXMD) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 600.0% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +61.7%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +61.7%, free cash flow -77.4% with operating margin 0.0% and ROIC -415.6%. Stock Foundry combines PXMD price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +61.7%, while operating margin sits near 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PXMD
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PXMD Max Drawdown
-98.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PXMD and SPY.
Company Overview
PaxMedica, Inc. Common Stock
Other OTC
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
- Leadership
- Howard J. Weisman
- IPO Date
- Aug 26, 2022
- Employees
- 6
- Street Address
- 303 South Broadway
- Mailing
- Tarrytown, NY, 10591
- Region
- Tarrytown, NY, US
- Reporting Currency
- USD
- Investor Line
- 914-987-2876
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- 0.3
- Price/Sales
- —
- Price/Book
- 0.0
Growth
- Revenue
- 0.0%
- EPS
- +61.7%
- Free Cash Flow
- -77.4%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -1047.0%
- ROIC
- -415.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 3.16
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.